Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients

被引：98

作者：

Bishop, E

Melvani, S

Howden, BP

Charles, PGP

Grayson, ML

机构：

[1] Austin Hlth, Dept Infect Dis, Heidelberg, Vic 3084, Australia

[2] Univ Melbourne, Dept Med, Melbourne, Vic, Australia

[3] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia

[4] Monash Univ, Dept Microbiol, Melbourne, Vic 3004, Australia

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 04期

关键词：

D O I：

10.1128/AAC.50.4.1599-1602.2006

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We assessed the toxicity and clinical outcomes associated with linezolid therapy (mean duration, 29 +/- 28 days; range, 8 to 185 days) in 44 patients with serious gram-positive infections. Although a clinical cure was achieved in 73% of the cases, 28/44 (64%) had adverse reactions (thrombocytopenia, n = 13; anemia, n = 7; gastrointestinal, n = 12; peripheral neuropathy, n = 1; serotonin syndrome, n = 1), such that a systematic monitoring protocol was developed.

引用

收藏

页码：1599 / 1602

页数：4

相关论文

共 18 条

[1] Linezolid-induced lactic acidosis. [J].

Apodaca, AA ;

Rakita, RM .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :86-87

[2] Thrombocytopenia associated with linezolid therapy [J].

Attassi, K ;

Hershberger, E ;

Alam, R ;

Zervos, MJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :695-698

[3] Serotonin syndrome after concomitant treatment with linezolid and citalopram [J].

Bernard, L ;

Stern, R ;

Lew, D ;

Hoffmeyer, P .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1197-1197

[4] Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].

Birmingham, MC ;

Rayner, CR ;

Meagher, AK ;

Flavin, SM ;

Batts, DH ;

Schentag, JJ .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168

[5] Oxazolidinone antibiotics [J].

Diekema, DJ ;

Jones, RN .

LANCET, 2001, 358 (9297) :1975-1982

[6] Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure [J].

Fiaccadori, E ;

Maggiore, U ;

Rotelli, C ;

Giacosa, R ;

Parenti, E ;

Picetti, E ;

Sagripanti, S ;

Manini, P ;

Andreoli, R ;

Cabassi, A .

CRITICAL CARE MEDICINE, 2004, 32 (12) :2437-2442

[7] Linezolid and serotonin toxicity [J].

Gillman, PK .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1274-1275

[8] Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility [J].

Howden, BP ;

Ward, PB ;

Charles, PGP ;

Korman, TM ;

Fuller, A ;

du Cros, P ;

Grabsch, EA ;

Roberts, SA ;

Robson, J ;

Read, K ;

Bak, N ;

Hurley, J ;

Johnson, PDR ;

Morris, AJ ;

Mayall, BC ;

Grayson, ML .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (04) :521-528

[9] Linezolid use associated with lactic acidosis [J].

Kopterides, P ;

Papadomichelakis, E ;

Armaganidis, A .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2005, 37 (02) :153-154

[10] Linezolid and serotonin syndrome [J].

Lavery, S ;

Ravi, H ;

McDaniel, WW ;

Pushkin, YR .

PSYCHOSOMATICS, 2001, 42 (05) :432-434